Clinical Trial

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis
Protocol Amendment History 16 amendments
This ClinicalTrials.gov record has been amended 16 times since 2024-08-19; most recent amendment 2025-11-14.
Status change: Recruiting → Active, Not Recruiting 2025-06-10
Status change: Not Yet Recruiting → Recruiting 2024-08-22
Trial Details
NCT Number NCT06564311
Lead Sponsor Zenas BioPharma (USA), LLC
Conditions Relapsing Multiple Sclerosis
Enrollment 93 participants
Start Date 2024-08-26
Primary Completion 2025-08-28 (estimated)
Study Completion 2026-02 (estimated)
Updated on ClinicalTrials.gov 2025-11-17